A Randomized controlled trial to compare effectiveness and side-effects of Brinzolamide and Dorzolamide among patients with high intra-ocular pressure

Abstract

Primary open angle glaucoma [POAG] is a chronic, progressive optic neuropathy in adults in which intraocular pressure (IOP) and other currently unknown factors contribute to damage of optic nerve. Reduction of elevated intraocular pressure is the only as yet proven approach to protect against visual field loss in patients with primary open angle glaucoma or ocular hypertension. First line therapy for elevated IOP is typically is a single topical agent like dorzolamid and brinzol amide. Aim: to compare effectiveness of dorzolamide and brinzolamide in lowering IOP. Methodology: This was a randomized controlled trial conducted at the Department of Ophthalmology, Jawahar Lal Nehru hospital, Ajmer, Rajasthan during the period from April 2017 to April 2018. A total of 52 patients (104 eyes) were initially enrolled in the study. Results: Topical brinzolamide 1% is found to be better than dorzolamide 2% as monotherapy for POAG and ocular hypertension as initial drug due to lower side effect and equal efficacy. Conclusion : The results of this study also indicate that both brinzolamide bid and dorzolamide t.i.d produced a clinically significant and equivalent lowering IOP in a large percentage of patients.